Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Sep;65(9):1233-6.
doi: 10.1136/ard.2005.048744. Epub 2006 Feb 13.

Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients

P Efthimiou  1 , S Schwartzman, L J Kagen
Affiliations

Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients

P Efthimiou et al. Ann Rheum Dis. 2006 Sep.

Abstract

Objective: To understand the use of tumour necrosis factor (TNF)alpha inhibitors in refractory dermatomyositis and polymyositis in an academic centre.

Methods: A retrospective study of eight patients with dermatomyositis or polymyositis refractory to corticosteroids and immunosuppressives who were treated with TNF inhibitors between 1998 and 2004.

Results: 8 patients with dermatomyositis or polymyositis who were treated with TNF inhibitors as adjunct treatment were identified. The mean (SD) duration of disease before initiation of TNF inhibitors was 8.5 (4.4) years. The patients failed to respond to treatment with corticosteroids (oral and intravenous); intravenous immunoglobulin and immunosuppressants (methotrexate, azathioprine, mycophenolate mofetil and leflunomide); 4.5 (1.4) immunosuppressants had been used before TNF treatment. Six patients were treated with etanercept alone, one with infliximab and one sequentially with both agents. Of the eight patients, six showed a favourable response with improved motor strength and decreased fatigue after 15.2 (6.5) months. Two of the patients did not respond after 4 (1.4) months and TNF inhibitors were discontinued. Responders showed a 54.4% (27.7%) decrease in serum concentration of creatine kinase, which was grossly abnormal (4463.5 (4036.4) U/l). Non-responders had similar reductions in creatine kinase concentration (56.1% (20.4%)), but their pre-treatment concentrations were in the normal range (118.5 (19.1) U/l).

Conclusion: Anti-TNF agents may be useful in some patients with refractory dermatomyositis or polymyositis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: SS is a member of the Speaker's Bureau for Centocor, Wyeth/Amgen, and Abbott Immunology. PE and LJK have no conflicts of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dalakas M C, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003362971–982. - PubMed
    1. Lundberg I E, Dastmalchi M. Possible pathogenic mechanisms in inflammatory myopathies. Rheum Dis Clin North Am 200228799–822. - PubMed
    1. Tateyama M, Nagano I, Yoshioka M, Chida K, Nakamura S, Itoyama Y. Expression of tumor necrosis factor‐alpha in muscles of polymyositis. J Neurol Sci 199714645–51. - PubMed
    1. Werth V P, Callen J P, Ang G, Sullivan K E. Associations of tumor necrosis factor alpha and HLA polymorphisms with adult dermatomyositis: implications for a unique pathogenesis. J Invest Dermatol 2002119617–620. - PubMed
    1. Gabay C, Gay‐Croisier F, Roux‐Lombard P, Meyer O, Maineti C, Guerne P A.et al Elevated serum levels of interleukin‐1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute‐phase protein response. Arthritis Rheum 1994371744–1751. - PubMed

MeSH terms